Premium
Dopaminergic activity of some simplified ergoline derivatives
Author(s) -
Euvrard Catherine,
Ferland Louise,
Fortin Michel,
Oberlander Claude,
Labrie Fernand,
Boissier Jacques R.
Publication year - 1981
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430010208
Subject(s) - bromocriptine , chemistry , dopaminergic , prolactin , endocrinology , medicine , dopamine , stimulation , dopamine agonist , agonist , apomorphine , pharmacology , biochemistry , hormone , biology , receptor
The dopamine (DA) agonist activity of new simplified ergoline derivatives (RU 27849, RU 28251, and RU 28306) was studied in comparison with bromocriptine. In contrast to bromocriptine, the three compounds were weak displacers of 3 H‐dihydroergocriptine or 3 H‐spiroperidol binding from bovine anterior pituitary or rat striatal membrane sites and weak inhibitors of prolactin secretion in anterior pituitary cells in culture. Similarly to bromocriptine, they did not induce changes in either the basal or the DA‐induced stimulation of the adenylate cyclase activities. In vivo, the three derivatives, at a low dose, increased plasma prolactin levels, decreased striatal DA turnover, and increased striatal acetylcholine content, as did bromocriptine. Furthermore, in 6‐OHDA‐lesioned rats, these molecules, like bromocriptine, induced an intense contralateral circling behavior. From their effectiveness in these different tests, the potencies of these new ergoline derivatives can be ranked in the following order : N‐propyl > N‐methyl > N‐H.